Topical Collection

Epigenetics of Melanoma

Message from the Collection Editor

The melanoma mutational landscape also includes genetic alterations in a number of epigenetic regulators. There is accumulating evidence that genetic alterations and changes in the expression or activity of ATP-dependent chromatin-modifying enzymes, histone modifying enzymes, and readers of the histone code, can drive melanoma pathogenesis. Re-wired transcriptional programs that drive tumorigenesis often involve interactions between chromatin regulators, oncogenic signaling pathways, and transcription factors.

This Topical Collection is focused on epigenetic reprogramming by ATP-dependent chromatin remodeling enzymes, histone-modifying enzymes and readers, in the regulation of gene expression involved in melanoma metabolism, proliferation, metastasis, and the response to anti-cancer drugs.

Collection Editor

Dr. Ivana De la Serna

Cancer Biology, College of Medicine and Life Sciences, University of Toledo, Toledo, OH 43614, USA



Epigenomes

an Open Access Journal by MDPI

Impact Factor 3.5 CiteScore 4.4 Indexed in PubMed



mdpi.com/si/77198

Epigenomes Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 epigenomes@mdpi.com

mdpi.com/journal/epigenomes





Epigenomes

an Open Access Journal by MDPI

Impact Factor 3.5 CiteScore 4.4 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

In the past years the growth of the epigenetic field has been outstanding, from here the need of a journal where to centralize all new information on the subject. The term epigenetics is now broadly used to indicate changes in gene functions that do not depend on changes in the sequence of DNA. *Epigenomes* covers all areas of DNA modification from single cell level to multicellular organism as well as the epigenetics on human pathologies and behavior.

Epigenomes (ISSN 2075-4655) is a fully peer-reviewed publication outlet with a rapid and economical route to open access publication. All articles are peer-reviewed and the editorial focus is on determining that the work is scientifically sound rather than trying to predict its future impact.

Fditor-in-Chief

Prof. Dr. Frnesto Guccione

Icahn School of Medicine at Mount Sinai, Hess Center for Science and Medicine, New York, NY 10029, USA

Author Benefits

High Visibility:

indexed within Scopus, ESCI (Web of Science), PMC, PubMed, Embase, PubAg, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Genetics and Heredity) / CiteScore - Q2 (Biochemistry, Genetics and Molecular Biology (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 20.3 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).